High-Dimensional Biology Linking Diseases with Genetics

Data science and AI analysis of complex multi-omics data are increasingly important in paving the way for novel personalized medicine and biotechnological applications. The use of advanced and continuously improving machine learning methodology enables theanalyzing of large data sets produced by multi-omics and other laboratory and clinical data that are surfacing as the new paradigm. The foundation will be the continuous improvements to omics technologies that lead to accurate and effective advances across all human diseases.

Moderator: Steve Gardner, PhD, Co-Founder & CEO, PrecisionLife
Steve has over 25 years’ experience building world-class teams, products and companies including as Global Director of Research Informatics for Astra. He has raised venture funding in the UK, EU and USA to develop and market highly innovative and commercially successful products in the life science, healthcare and food industries. Steve specialises in AI-enabled precision medicine, drug discovery, large-scale genomics, semantic data integration and complex data analytics for life science, healthcare and clinical decision support. Steve is an Advisory Council member for Breast Cancer Now and is on the Steering Committee of the UKCRC Tissue Coordination Centre.

Lisa Alderson, MBA, CEO & Co-Founder, Genome Medical, Inc.
Lisa Alderson is the CEO and Co-Founder of Genome Medical, Inc., a leading genomics technology and services company that is transforming the delivery of medicine by enabling access to genomic-based medicine for everyday care. Through its nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, Genome Medical provides health expertise throughout the genomics journey. Prior, Ms. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was also the former CEO and president of CrossLoop Inc., a marketplace for technical services (acquired by Nasdaq: AVG). Prior to that, she was part of the start-up team at Genomic Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc., (acquired by Nasdaq: GAIA) and the former manager of strategic planning at The Walt Disney Co. Lisa also serves on the board of the Kidney Cancer Association. She has a track record of creating, funding and managing high-growth ventures. Lisa has an MBA with distinction from Harvard Business School and a BA from Colorado State University, where she graduated Summa Cum Laude.

Jay Goth, Founder & CEO, Murrieta Genomics; President, SimplSeq, Inc.
Jay Goth is the CEO of Murrieta Genomics and President of SimplSeq, Inc. He is the former Managing Partner of Forentis Fund, a biotech venture capital firm that was focused on biomarker discover, data analytics and precision medicine. He serves as Executive Director of InSoCal CONNECT, a nonprofit that has structured mentorship and training programs for entrepreneurs, was a Senior Consultant with TriTech SBDC, one of seven technology designated Small Business Development Centers operating under the SBA, and served as an Entrepreneur in Residence at the University of California, Riverside. He holds board positions with several for-profit and non-profit enterprises.

Yatin Mundkur, CEO, Cellworks Group
Committed to the delivery of Precision Medicine for cancer care, Yatin Mundkur leads Cellworks Group in transforming the treatment of cancer through personalized medicine. As CEO of Cellworks, Yatin Mundkur develops company strategy and commercialization of both its Precision Medicine and its Stratified Medicine businesses. Over the last 25 years, Yatin has launched businesses in medical diagnostics, technology and communications, delivering strong returns to investors consistently. As a Partner of Artiman Ventures he focuses on early-stage Technology and Healthcare investments. He is also on the Boards of Prysm, mSupply, Virsec, Xambala, Yantra and zSpace. Prior to joining Artiman Ventures, Yatin Mundkur was Managing Director at TeleSoft Partners, where he led investments in over twenty companies, in the early stage semiconductor and software sectors. Formerly, he held executive and engineering roles in multiple technology companies. He has been awarded fourteen patents, in the areas of computer architectures, digital consumer electronics, semiconductor design, and software. Yatin holds a B.S.E.E. from MSU of Baroda, India, and a M.S.E.E. from the University of Texas at Austin.

Leila Pirhaji, PhD, Founder & CEO, ReviveMed
Dr. Leila Pirhaji is the Founder and CEO of ReviveMed with a PhD in Bioengineering from MIT, where she developed a pioneering artificial intelligence (AI) technology to identify a large number of small molecules or metabolites from blood or tissues of patients rapidly, and translate their data into drug discovery insights. She then founded ReviveMed to bring this technology to the market. Her innovative work has received several prestigious awards and featured in TV and media outlets. In 2019, Leila gave a TED talk on the medical applications of AI and metabolomics, which has been viewed >1.7 M times. In 2020, Leila was named as a 35 innovator under 35 by the MIT Technology Review.